LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Alnylam Pharmaceuticals Inc

Fechado

SetorSaúde

300.93 -2.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

299.82

Máximo

308.97

Indicadores-chave

By Trading Economics

Rendimento

26M

-57M

Vendas

1M

594M

EPS

-0.01

Margem de lucro

-9.674

Funcionários

2,230

EBITDA

166M

11M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+6.48% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.7B

40B

Abertura anterior

303.18

Fecho anterior

300.93

Sentimento de Notícias

By Acuity

50%

50%

166 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Alnylam Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

12 de set. de 2024, 17:01 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 de set. de 2024, 11:00 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Alnylam Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

6.48% parte superior

Previsão para 12 meses

Média 327.95 USD  6.48%

Máximo 500 USD

Mínimo 245 USD

Com base em 23 analistas de Wall Street que oferecem metas de preço de 12 meses para Alnylam Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

23 ratings

19

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

256.565 / 269.81Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

166 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.